-
Amylyx Pharmaceuticals NASDAQ:AMLX Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Location: | Website: www.amylyx.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
148.6M
Cash
234.4M
Avg Qtr Burn
-23.77M
Short % of Float
3.62%
Insider Ownership
14.32%
Institutional Own.
82.47%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Relyvrio (AMX0035) Details Amyotrophic lateral sclerosis | Approved Update | |
AMX0035 Details Progressive supranuclear palsy | Phase 3 Data readout | |
Relyvrio (AMX0035) Details Amyotrophic lateral sclerosis | Phase 3 Update | |
Avexitide Details Hyperinsulinism, Post-Bariatric Hypoglycemia, Congenital Hyperinsulinism | Phase 3 Initiation | |
AMX0035 Details Alzheimer's disease | Phase 2 Update | |
AMX0035 Details Wolfram syndrome | Phase 2 Update | |
AMX0114 Details Amyotrophic lateral sclerosis | Phase 1 Initiation |